Monopar Therapeutics (MNPR) Interest Coverage Ratio (2017 - 2026)

Monopar Therapeutics (MNPR) posted Interest Coverage Ratio of 36.94 for Q3 2025, down 41.73% sequentially from 26.06 in Q2 2025.

Monopar Therapeutics (MNPR) Interest Coverage Ratio (2017 - 2026) Analysis & Trends

Monopar Therapeutics has reported Interest Coverage Ratio for 7 years, with the latest figure at 36.94 in Q3 2025.

Quarterly Interest Coverage Ratio changed N/A year-over-year to 36.94 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 109.42 (changed N/A YoY) and the FY2025 annual result came in at 0.38, up 187.73% from the prior year.
Interest Coverage Ratio eased to 36.94 in Q3 2025 per MNPR's latest filing, from 26.06 in the prior quarter.
Over five years, Interest Coverage Ratio peaked at 0.26 in Q4 2022 and troughed at 805454.25 in Q1 2025.
A 3-year average of 100847.0 and a median of 34.77 in 2022 frame the typical range for Interest Coverage Ratio.
The sharpest annual moves came in 2021 and 2022: Interest Coverage Ratio gained 19.81% in 2021, then grew 24.82% in 2022.
Over 3 years, Interest Coverage Ratio stood at 0.35 in 2021, then climbed by 24.82% to 0.26 in 2022, then plunged by 14048.61% to 36.94 in 2025.
According to Business Quant data, Interest Coverage Ratio over the past three periods registered 36.94, 26.06, and 805454.25 for Q3 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Cover (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.84
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	24.64
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-0.19
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	8.18
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.01
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.61
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.82
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.08
10	Monopar Therapeutics	965.64 Mn	912.88 Mn	-	-30.14

Download Data